Arcadia Biosciences, Inc. (RKDA) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
RKDA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RKDA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 36.2% | -205.7% | -48.1% |
| 2024 | 41.3% | -72.3% | -139.5% |
| 2023 | 51.2% | -137.0% | -313.9% |
| 2022 | 17.8% | -188.8% | -207.3% |
| 2021 | -28.4% | -524.0% | -216.2% |
Download Data
Export RKDA earnings history in CSV or JSON format
Free sign-in required to download data
Arcadia Biosciences, Inc. (RKDA) Earnings Overview
As of May 8, 2026, Arcadia Biosciences, Inc. (RKDA) reported trailing twelve-month net income of -$2M, reflecting +66.9% year-over-year growth. The company earned $-1.71 per diluted share over the past four quarters, with a net profit margin of -48.1%.
Looking at the long-term picture, RKDA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2025, representing a new all-time high.
Arcadia Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PGEN (-$247M net income, -3216.2% margin), OFIX (-$60M net income, -11.2% margin), SEED (-$43M net income, -58.4% margin), RKDA has outperformed on profitability metrics. Compare RKDA vs PGEN →
RKDA Earnings vs Peers
Earnings metrics vs comparable public companies
RKDA Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$2M | +66.8% | -$10M | $-1.71 | -48.1% | -205.7% |
| 2024 | -$7M | +49.7% | -$4M | $-5.16 | -139.5% | -72.3% |
| 2023 | -$14M | +9.1% | -$6M | $-11.30 | -313.9% | -137.0% |
| 2022 | -$15M | -4.9% | -$14M | $-26.05 | -207.3% | -188.8% |
| 2021 | -$15M | -214.9% | -$36M | $-30.33 | -216.2% | -524.0% |
| 2020 | -$5M | +83.8% | -$13M | $-24.20 | -57.9% | -159.0% |
| 2019 | -$29M | -113.7% | -$19M | $-181.50 | -2464.1% | -1657.9% |
| 2018 | -$13M | +14.2% | -$17M | $-143.16 | -920.8% | -1152.3% |
| 2017 | -$16M | +20.0% | -$14M | $-291.38 | -390.1% | -355.6% |
| 2016 | -$20M | -9.3% | -$19M | $-353.85 | -615.6% | -584.1% |
See RKDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RKDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RKDA vs LIN
Side-by-side business, growth, and profitability comparison vs Linde plc.
Start ComparisonRKDA — Frequently Asked Questions
Quick answers to the most common questions about buying RKDA stock.
Is RKDA growing earnings?
RKDA EPS is $-1.71, with earnings growth accelerating to +66.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-2M.
What are RKDA's profit margins?
Arcadia Biosciences, Inc. net margin is -48.1%, with operating margin at -205.7%. Below-average margins reflect competitive or cost pressures.
How consistent are RKDA's earnings?
RKDA earnings data spans 2012-2025. The accelerating earnings trend is +66.9% YoY. Historical data enables comparison across business cycles.